Overview

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study is to evaluate the safety and tolerability of itacitinib in combination with docetaxel and to select doses for further evaluation (Part 1, safety run-in portion).
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation
Treatments:
Docetaxel